Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3-Internal Tandem Duplication Mutation (SORMAIN).

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
A BurchertS K Metzelder

Abstract

Despite undergoing allogeneic hematopoietic stem cell transplantation (HCT), patients with acute myeloid leukemia (AML) with internal tandem duplication mutation in the FMS-like tyrosine kinase 3 gene (FLT3-ITD) have a poor prognosis, frequently relapse, and die as a result of AML. It is currently unknown whether a maintenance therapy using FLT3 inhibitors, such as the multitargeted tyrosine kinase inhibitor sorafenib, improves outcome after HCT. In a randomized, placebo-controlled, double-blind phase II trial (SORMAIN; German Clinical Trials Register: DRKS00000591), 83 adult patients with FLT3-ITD-positive AML in complete hematologic remission after HCT were randomly assigned to receive for 24 months either the multitargeted and FLT3-kinase inhibitor sorafenib (n = 43) or placebo (n = 40 placebo). Relapse-free survival (RFS) was the primary endpoint of this trial. Relapse was defined as relapse or death, whatever occurred first. With a median follow-up of 41.8 months, the hazard ratio (HR) for relapse or death in the sorafenib group versus placebo group was 0.39 (95% CI, 0.18 to 0.85; log-rank P = .013). The 24-month RFS probability was 53.3% (95% CI, 0.36 to 0.68) with placebo versus 85.0% (95% CI, 0.70 to 0.93) with sorafeni...Continue Reading

References

Jan 18, 1994·Proceedings of the National Academy of Sciences of the United States of America·D SmallA M Gewirtz
Dec 13, 2005·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Alexandra H FilipovichMary E D Flowers
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jan 10, 2008·Nature Biotechnology·Mazen W KaramanPatrick P Zarrinkar
Jan 31, 2008·Journal of the National Cancer Institute·Weiguo ZhangMichael Andreeff
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Salut BrunetVanderson Rocha
Jul 31, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hubert ServeWolfgang E Berdel
Sep 23, 2014·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yi-Bin ChenRobert Soiffer
Sep 20, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Andrew C HarrisJohn E Levine
Dec 17, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daisuke ArakiRoland B Walter
Jan 21, 2016·The New England Journal of Medicine·Adam IveyUNKNOWN UK National Cancer Research Institute AML Working Group
Jun 9, 2016·The New England Journal of Medicine·Elli PapaemmanuilPeter J Campbell
Nov 23, 2016·Blood·Keith W Pratz, Mark Levis
Jun 24, 2017·The New England Journal of Medicine·Richard M StoneHartmut Döhner
Aug 2, 2017·The Lancet Oncology·Naval Daver, Hagop Kantarjian
Oct 22, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S K MetzelderA Burchert
Mar 31, 2018·The New England Journal of Medicine·Mojca Jongen-LavrencicPeter J M Valk
Apr 28, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kiyomi MoritaKoichi Takahashi

❮ Previous
Next ❯

Citations

Aug 28, 2020·Nature Reviews. Clinical Oncology·Diana Romero
Sep 22, 2020·Minerva medica·Adrián Mosquera OrgueiraClaudio Cerchione
Jan 9, 2021·Expert Review of Clinical Pharmacology·Mahesh Swaminathan, Eunice S Wang
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aideen T O'Neill, Ronjon Chakraverty
Jan 13, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph SchmidGesine Bug
Jan 5, 2021·Current Opinion in Hematology·Rory M Shallis, Nikolai A Podoltsev
Sep 24, 2020·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bhagirathbhai DholariaArnon Nagler
Feb 6, 2021·Leukemia & Lymphoma·Julian A Waksal, Martin S Tallman
Jan 12, 2021·Frontiers in Oncology·Vanessa E Kennedy, Catherine C Smith
Nov 21, 2020·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Iku KamitaniShingo Yano
Feb 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shigeo Fuji
Feb 24, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andreas BurchertCarmen Schade-Brittinger
Feb 20, 2021·Frontiers in Oncology·Patrick K Reville, Tapan M Kadia
Feb 24, 2021·Blood Cancer Journal·Hagop KantarjianFarhad Ravandi
Mar 24, 2021·Blood Advances·Firas El ChaerChristopher S Hourigan
Mar 25, 2021·Journal of Hematology & Oncology·Hongtao Liu
Mar 26, 2021·Best Practice & Research. Clinical Haematology·Mark Levis
Apr 10, 2021·Blood Reviews·Marcos de LimaGert Ossenkoppele
Apr 11, 2021·Transplantation and Cellular Therapy·Eduardo Rodríguez-ArbolíUNKNOWN PETHEMA (Programa Español de Tratamientos en Hematología) and GETH (Grupo Español de Trasplante Hematopoyético y Terapia Cel
Apr 16, 2021·Expert Opinion on Drug Safety·Giovanni MarconiGiovanni Martinelli
Aug 14, 2020·The Lancet Oncology·Mohamad Mohty
Apr 26, 2021·Seminars in Cancer Biology·Jörg Westermann, Lars Bullinger
Mar 30, 2021·Journal of Internal Medicine·V Lj Lazarevic
May 20, 2021·Nature Reviews. Clinical Oncology·Hartmut DöhnerBob Löwenberg
May 29, 2021·Blood Cancer Journal·Naval DaverFarhad Ravandi
May 21, 2021·Frontiers in Immunology·Justin LokeCharles Craddock
May 18, 2021·Therapeutic Advances in Hematology·Kimberley DoucetteCatherine Lai
Jun 3, 2021·International Journal of Molecular Sciences·Michael LoschiThomas Cluzeau
Jun 8, 2021·HemaSphere·Felicitas Thol, Michael Heuser

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.